Advanced Magnetic Resonance Imaging Measures of Repair in Alemtuzumab Treated Patients

Trial Profile

Advanced Magnetic Resonance Imaging Measures of Repair in Alemtuzumab Treated Patients

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2016

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Acronyms iCAMMS-IST
  • Most Recent Events

    • 11 Dec 2013 Planned end date changed from 1 Feb 2018 to 1 Dec 2018 as reported by ClinicalTrials.gov.
    • 11 Dec 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
    • 17 Jan 2013 Planned number of patients changed from 20 to 25 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top